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was sent to all 14 provincial cancer centres in 2013. The survey 
included 72 questions in four different categories: 
general/demographic, pre-treatment assessment, EBRT and BT 
questions.  
Results: The response rate was 100%. Ten out of 14 centres 
treated cervical cancer patients and had a dedicated 
brachytherapy suite. All 10 centres that treated cervix cancer 
had a peer review process for quality assurance (QA). Nine 
centres had written treatment planning and delivery protocol 
and five centres used a specific plan evaluation protocol for 
organs at risk for EBRT. The standard EBRT technique was 4-field 
box in eight centres and one centre used IMRT if treating the 
para-aortic nodes simultaneously; one centre did not respond. 
The dose/fractionation scheme to the whole pelvis was 45-50 Gy 
in 1.8-2 Gy per fraction in all but one centre. Nine centres used 
image verification at some point during EBRT. All ten centres 
used HDR brachytherapy and one centre also used PDR 
brachytherapy to treat cervix cancer patients.  
Brachytherapy was performed under general anesthesia, regional 
anesthesia and conscious sedation in four, one and five centres, 
respectively. Only one centre offered interstitial brachytherapy. 
The majority of centres (eight of 10) used ultrasound image 
guidance for intrauterine applicator insertion. For treatment 
planning two centres used CT and MRI, four centres used CT only 
and four centres used orthogonal x-rays. GEC-ESTRO guidelines 
were used in three centres for target volume delineation and in 
five centres for organs at risk (OAR) dose constraints. Nine 
centres prescribed and reported dose to Point A. Volumetric dose 
prescription was performed in one centre and four centres 
reported dose to a target volume. Eight centres reported dose to 
OARs. The number of BT applicator insertions varied significantly 
between the centres ranging from one to six. The dose 
prescription was also variable ranging from 5.5 Gy to 8 Gy per 
fraction. 
Conclusions: The main findings from the survey were the 
variation in the BT dose fractionation and treatment planning 
used in the regional cancer centres while there was a general 
uniformity in peer reviewed QA, written institutional treatment 
protocol, EBRT technique, dose fractionation scheme and use of 
HDR BT across the province. This study shed light on the need to 
implement a harmonized evidence-based brachytherapy practice 




FEASIBILITY OF COLLECTING PATIENT REPORTED OUTCOMES FOR 
PATIENTS RECEIVING CURATIVE INTENT RT FOR GYNECOLOGICAL 
MALIGNANCIES  
Robert Olson1, Caroline Holloway2, Christina Parson3, Peter 
Lim2, Vincent Lapointe4, Sheri Lomas4, Gale Bowering5, Francois 
Bachand6 
1British Columbia Cancer Agency - Centre for the North, Prince 
George, BC 
2University of British Columbia, Victoria, BC 
3University of British Columbia, Vancouver, BC 
4British Columbia Cancer Agency, Vancouver, BC 
5British Columbia Cancer Agency, Abbotsford, BC 
6University of British Columbia, Kelowna, BC 
 
Purpose: The British Columbia Cancer Agency radiotherapy (RT) 
program started the Prospective Outcomes and Support Initiative 
(POSI) at all six centres in 2013 to collect and utilize patient 
reported outcomes (PROs) for patients receiving palliative intent 
RT. In 2015 it expanded to patients receiving curative intent RT, 
starting with the gynecological (gyne) tumour group. We sought 
to describe the success in expanding to non-palliative sites. 
Methods and Materials: Five validated questionnaires, the EPIC 
Bowel 2 (2002), EPIC Urinary 2 (2002), PRO-CTAE GI toxicity, 
EORTC QLQ CX24, and the EQ5DL were selected as the PROs of 
interest by the gyne tumour group. The questionnaires were 
converted to tablet format, and data was entered directly by 
patients via tablet at time of RT, and each subsequent follow up 
(FU). Some centres choose to also administer the questions 
weekly during RT, which is categorized as FU below in comparing 
scores to baseline. The results of the questionnaires were made 
available immediately to Radiation Oncologists, viewable in the 
RT electronic medical record, and in a local intranet POSI Portal. 
Descriptive Statistics were used to present accrual data and 
results of the PRO questionnaires. 
Results: From March 2015 to January 2016, 480 gyne patients 
were approached by POSI on 1007 occasions (i.e. baseline, on 
treatment, or FU), with a 97% response rate. However, not all six 
British Columbia Cancer Agency centres participated at that 
time, with Vancouver and Victoria starting in March, Abbotsford 
in July, Kelowna in August, while Surrey and Prince George have 
not yet participated. The mean (and standard deviation) scores 
of the EPIC Bowel, EPIC Urinary, PRO-CTAE GI, EORTC QLQ CX24, 
and EQ5DL were 8.9 (9.4), 6.1 (7.3), 2.9 (3.4), 2.8 (3.5), and 8.8 
(3.2), respectively, with significantly (p < 0.05) worse scores at 
FU compared to baseline for each questionnaire, except the 
EQ5DL (p = 0.62). Of the 24 patients not accrued, 29% were unfit, 
21% had not interpreter available, and 50% declined. Among 
those who declined, 33% did at baseline, 17% at first repeat 
measure, 25% at second, and 25% at the third or later repeat 
measure. Among the 189 patients who reported PRO on more 
than one time interval, 72, 37, and 80 patients repeated the PRO 
2,3, and > 3 occasions respectively to date. 
Conclusions: Expansion of POSI to collect PRO in a radical 
tumour group appears feasible, though there have been barriers 
to expansion to all six British Columbia Cancer Agency centres, 
which will be explored. Despite the use of five validated 
questionnaires totaling 49 questions, the accrual rate is 
exceptional, and appears feasible weekly during radiotherapy. 
Expansion to other radical tumour sites will be used to test if 
these results are reproducible. Future plans are to test the 
impact of providing PRO data to clinicians, and to make gyne PRO 
data available for research and quality improvement initiatives. 
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Purpose: The EORTC 22881 boost trial showed a substantial 
benefit of delivering a radiotherapy boost to the tumour bed 
(RTB) in women aged 40 years and younger, with an improvement 
in 10-year local relapse-free survival (LRFS) of 10%. However, 
this trial was carried out in an era where pre-menopausal women 
did not receive adjuvant hormone therapy (HT). We sought to 
determine how the use of HT and RTB changed in a population-
based cancer care program in response to new practice 
guidelines, and whether this had an impact on LRFS. We also set 
out to determine whether the anticipated benefit of a RTB for 
young women was observed in the era of routine HT.  
Methods and Materials: A provincial database was used to 
identify all women 40 years and younger with breast cancer that 
met the inclusion criteria of the EORTC 22881 trial: treated with 
whole breast radiotherapy after breast conserving surgery, 
margin negative (not at ink), and Stage I and II. The percentages 
of women receiving HT and RTB were compared across three Eras 
that were defined, a priori, with a three-month delay allowing 
for implementation of the practice changes: Era 1 (pre-HT, pre-
boost) January 1996-September 1998; Era 2 (HT, pre-boost) 
January 1999 - September 2001; Era 3 (HT and boost) January 
2002 - September 2004. LRFS was calculated using the Kaplan-
Meier method and the three eras compared using a log rank test. 
Factors significant at < 0.3 on univariate analysis were included 
with Era in a multivariable (MVA) Cox model. 
Results: The study included 411 patients: 130 in Era 1, 142 in Era 
2, and 139 in Era 3. The use of adjuvant HT increased over time, 
with 8% use in Era 1, 45% in Era 2 and 54% in Era 3 (p = < 0.001) 
For estrogen receptor (ER) positive cancers, HT use was higher: 
13% in Era 1, 68% in Era 2 and 82% in Era 3 (p = < 0.0001). The 
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use of RTB after adjuvant breast radiotherapy was 38% in Era 1, 
29% in Era 2 and 76% in Era 3 (p < 0.001). Ten-year LRFS was 
85.3% in Era 1, 93.9% in Era 2 and 91.9% in Era 3. On MVA there 
was a significant decrease in relapse going from Era 1 (pre-HT, 
pre-boost) to Era 2 (HT, no boost) (HR 2.2, p = 0.03), but no 
change in relapse from Era 2 (HT, no boost) to Era 3 (HT and 
boost) (HR 1.0, p = 0.97). For LRFS across all three eras, there 
was no significant difference for patients that received a boost 
(92.9%) and those that did not (88.6%, p = 0.31) but there was a 
significant improvement for ER-positive patients that received 
HT (91.8% versus 81.6%, p = 0.01).  
Conclusions: This study showed that new breast cancer 
therapies were adopted swiftly in response to new clinical 
practice guidelines. The introduction of HT was associated with 
an 8.6% improvement in ten-year LRFS. However, for a 
population of patients that was routinely prescribed HT, no 
improvement in LRFS was observed with the addition of routine 
RTB. RTB causes toxicity and offers no survival benefit; its 
routine use should be re-evaluated in the HT era.  
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Purpose: To determine whether DIBH produced a clinically 
meaningful reduction in pulmonary dose in comparison to free 
breathing (FB) during adjuvant locoregional radiation (RT) for 
right-sided breast cancer. 
Methods and Materials: Thirty women with Stages 0-I left-sided 
breast cancer and who had both DIBH and FB CT scans as part of 
standard care were included. The right-sided IMC nodes were 
contoured according to ESTRO guidelines on DIBH and FB scans, 
with care taken to ensure comparability between scans. A four-
field, modified-wide tangent RT plan was developed on each 
scan to include the right breast and full regional nodes, including 
a minimum dose of 80% to the IMC volume. The junction between 
the supraclavicular and tangent fields was at the inferior extent 
of the ossified medial clavicle. Treatment plans were calculated 
in Eclipse using the Acuros algorithm version 11. FB and DIBH plan 
metrics were compared using Wilcoxon-signed rank testing. 
Results: IMC coverage was equivalent between DIBH and FB 
plans; V80 was 100% on both plans and D100 was 39.2 and 39.5 
Gy for DIBH and FB, respectively. Twenty-one patients (70%) had 
≥ 5% reduction in ipsilateral lung V20 with DIBH compared to FB. 
The average ipsilateral lung V20 decreased by 7.8% (range: 0 to 
20%; p < 0.001) and the mean lung dose decreased by 3.4 Gy with 
DIBH (range: -0.2 to 9.1; p < 0.001). The right lung absolute V20 
Gy gain from DIBH was larger among 15 patients with the highest 
V20 compared to 15 patients with the lowest V20 on FB (10.1% 
versus 5.6% respectively; p = 0.01). There was a mean reduction 
of 42.3 cc (range: 0 to 178.9; p < 0.001) in the volume of liver 
receiving 50% of the prescription dose. The differences in mean 
heart doses were statistically significant, but not likely clinically 
significant: MHD was 0.88 Gy (range: 0.67 to 1.27) and 1.00 Gy 
(range: 0.75 to 1.48) (p < 0.001) for DIBH and FB, respectively.  
Conclusions: DIBH reduced mean ipsilateral lung V20 by 7.8% and 
mean lung dose by 3.4 Gy. For some patients, the volume of liver 
receiving ≥ 25 Gy can also be reduced with DIBH. DIBH should be 
available as a treatment strategy to reduce right lung V20 
without compromising IMC or supraclavicular nodal coverage for 
patients with right-sided breast cancer during locoregional RT. 
This strategy can be advantageous in cases where the ipsilateral 
V20 on FB approaches 30%, a value that prompts many radiation 
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Purpose: Randomized clinical trials have shown equivalent local 
control for patients with early-stage breast cancer (BC) treated 
with conventional fractionation (CF) or hypofractionated (HF) 
adjuvant whole breast radiotherapy (WBRT). However, women 
less than 50 years of age have been underrepresented in these 
trials, and controversy still remains in relation to optimal 
fractionation schedule in this patient group. Our institutional 
policy allows for both schedules, therefore we compared local 
control in young women following breast-conserving surgery 
(BCS), and identified factors associated with recommendation of 
CF or HF schedule. 
Methods and Materials: Two hundred and seventy-one women 
under 50 years of age with early-stage invasive BC (pT1-T2, pN0) 
treated from September 2009 to December 2013 were identified 
from an institutional database. BCS was followed by adjuvant CF 
(50 Gy in 25 fractions) or HF (40 or 42.4 Gy in 16 fractions) WBRT, 
followed by a boost to the tumour bed of 10-16 Gy in in 5-8 
fractions. Data on tumour characteristics and adjuvant systemic 
therapies were collected. Length of follow up was calculated 
from the completion date of radiotherapy (RT) to the date of 
most recent imaging or clinical review in which disease status 
was recorded. 
Results: Two hundred and twenty-seven (83.8%) patients were 
treated with HF and 44 (16.2%) with CF WBRT. Median follow up 
was 2.9 years (range 0-5.8 years) and median age was 42.8 years 
(range 19-49 years). Most patients had invasive ductal carcinoma 
(94%), unifocal (86%), Grade 1 or 2 (65%) and ER positive (88%) 
disease, of which 81% received adjuvant endocrine therapy. 
Lymphovascular invasion was associated in 16%, 54% received 
adjuvant systemic chemotherapy, 14% had HER2-positive disease 
and 8.5% of cases were triple negative (TN). Local control was 
achieved in 225 (99.1%) and 43 (97.7%) patients in the HF and CF 
groups, respectively. The mean age (± standard deviation) of 
patients receiving HF was 43.5 ± 4.5 years, and 39.3 ± 7.5 years 
for the CF group (p < 0.01). On univariate analysis, age greater 
than 40 years was associated with a higher likelihood of receiving 
HF WBRT (OR = 2.52, 95% CI 1.32-4.87), and patients with TN 
disease were 67% more likely to receive CF WBRT (OR = 0.33, 95% 
CI 0.13-0.87). No other differences were identified between the 
CF and HF groups, including receipt of systemic therapies. 
Conclusions: Young women with early-stage BC treated with HF 
WBRT following BCS obtained excellent local control that was 
comparable to CF WBRT. At our institution, HF was more likely 
to be recommended for women over 40 years of age or for non-
TN BC in this patient population. HF WBRT shortens total 
treatment time, is more convenient for patients and may be 
considered for women less than 50 years of age. 
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Purpose: Recent literature has suggested that higher volumes of 
practice are associated with better survival outcomes for head 
and neck cancer (HNC) patients. Some limitations in these 
studies, however, include looking at the volume of practice on a 
cancer centre level, not a provider level, and not controlling for 
rurality of patient residence. The primary objective of this study 
was to evaluate the effect of treatment centre on the overall 
survival (OS) and cancer-specific survival (CSS) of HNC patients 
